Drug Profile
Research programme: norovirus vaccine - Daiichi Sankyo/UMN Pharma
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; UMN Pharma
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Norovirus infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Norovirus-infections(Prevention) in Japan (Parenteral)
- 14 Feb 2014 Daiichi Sankyo and UMN Pharma agree to co-develop norovirus vaccine in Japan for Norovirus infections
- 14 Feb 2014 Early research in Norovirus infections (prevention) in Japan (Parenteral)